Hemochromatosis and Iron Overload Screening Study (HEIRS)
Note that you will be prompted to log in or register an account
Accession Number
HLB00690919a
Study Type
Epidemiology Study
Collection Type
Open BioLINCC Study
See bottom of this webpage for request information
Study Period
January 2000 - January 2006
NHLBI Division
DCVS
Dataset(s) Last Updated
May 3, 2019
Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00005541
Primary Publication URLs
N/A
Consent
Commercial Use Data Restrictions No
Data Restrictions Based On Area Of Research Yes
Commercial Use Specimen Restrictions No
Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes
Genetic Use Of Specimens Allowed? Yes
Genetic Use Area Of Research Restrictions Yes
Specific Consent Restrictions
Use of biospecimens and data is generally restricted to iron-related and hereditary hemochromatosis studies. A subset of biospecimens and data are available for broader use.
Objectives
The HEIRS Study evaluated the prevalence and genetic and environmental determinants and potential clinical, personal, and societal impact of iron overload and hereditary hemochromatosis in a multi-center, multiethnic, primary care-based sample of adults.
Background
Hereditary iron overload, or hemochromatosis, is a common inherited disorder resulting from overabsorption of dietary iron. Excess iron is deposited in body tissues, and can accumulate to toxic levels over time causing damage in multiple organ systems. If untreated, these conditions may lead to death. Evidence suggests that early diagnosis and treatment can prevent disease manifestations and enable normal life expectancy. Thus, hemochromatosis may be suitable for detection and intervention through primary care screening strategies; however, much remains to be learned about the penetrance and expression of the known gene variants, HFE C282Y and H63D, associated with hemochromatosis. Iron overload and hereditary hemochromatosis have not been as extensively studied in racial/ethnic groups other than Caucasians.
Participants
The initial screen phase included 102,000 adults recruited over a 2-year period from 5 North American Field Centers (approx. 51% white, 24% African American, 11% Asian, 11% Hispanic, and 3% unidentified race; 63% are female and 37% are male).
Design
During the initial screen phase in 2001-2002, participants were recruited from primary care practices and blood-drawing laboratories. Blood specimens were tested for transferrin saturation (TS), serum ferritin (SF), and HFE C282Y and H63D genetic variants. Before genetic screening, participants were asked whether they had a history of medical conditions related to iron overload. Those participants with elevated iron levels and/or C282Y homozygosity, their family members, and frequency-matched control participants completed an examination that obtained data on personal and family medical history, lifestyle characteristics, genetic counseling and assessment of ethical, legal and social implications of screening, as well as clinical and biochemical measures. A separate randomized study examined the acceptability of genotypic or phenotypic (biochemical) screening for hemochromatosis.
The majority of HEIRS participants have a consent limited to research on iron related disorders; however, specimens and data from ~6770 participants are available for broader research use.
Conclusions
Findings include: 1) transferrin saturation (TS) and serum ferritin (SF) mean levels differ across race/ethnic groups; 2) HFE C282Y variant does not account for these levels in non-Caucasians (Adams et al, NEJM 352:1769-78, 2005); and 3) there is similar participant acceptance for genotypic as for phenotypic testing (Anderson et al, Genet Med. 7:557-63, 2005).
Additional Details
Cases: 1678
Controls: 641
Screened Only: 99623
|
Screened Only |
Case |
Control |
All |
||||
---|---|---|---|---|---|---|---|---|
N |
% |
N |
% |
N |
% |
N |
% |
|
Missing |
123 |
0.12 |
. |
. |
. |
. |
123 |
0.12 |
25-29 |
7209 |
7.24 |
62 |
3.69 |
29 |
4.52 |
7300 |
7.16 |
30-34 |
8734 |
8.77 |
90 |
5.36 |
30 |
4.68 |
8854 |
8.69 |
35-39 |
9771 |
9.81 |
120 |
7.15 |
44 |
6.86 |
9935 |
9.75 |
40-44 |
11265 |
11.31 |
153 |
9.12 |
50 |
7.80 |
11468 |
11.25 |
45-49 |
12397 |
12.44 |
218 |
12.99 |
89 |
13.88 |
12704 |
12.46 |
50-54 |
12580 |
12.63 |
258 |
15.38 |
83 |
12.95 |
12921 |
12.67 |
55-59 |
10789 |
10.83 |
211 |
12.57 |
87 |
13.57 |
11087 |
10.88 |
60-64 |
9099 |
9.13 |
192 |
11.44 |
61 |
9.52 |
9352 |
9.17 |
65-69 |
6860 |
6.89 |
158 |
9.42 |
69 |
10.76 |
7087 |
6.95 |
70-74 |
5049 |
5.07 |
97 |
5.78 |
47 |
7.33 |
5193 |
5.09 |
75-79 |
3413 |
3.43 |
77 |
4.59 |
32 |
4.99 |
3522 |
3.45 |
80-84 |
1676 |
1.68 |
33 |
1.97 |
17 |
2.65 |
1726 |
1.69 |
85-89 |
506 |
0.51 |
9 |
0.54 |
2 |
0.31 |
517 |
0.51 |
90 |
152 |
0.15 |
. |
. |
1 |
0.16 |
153 |
0.15 |
|
Screened Only |
Case |
Control |
All |
||||
---|---|---|---|---|---|---|---|---|
N |
% |
N |
% |
N |
% |
N |
% |
|
Missing |
12 |
0.01 |
. |
. |
. |
. |
12 |
0.01 |
Male |
36686 |
36.82 |
930 |
55.42 |
240 |
37.44 |
37856 |
37.13 |
Female |
62925 |
63.16 |
748 |
44.58 |
401 |
62.56 |
64074 |
62.85 |
|
Screened Only |
Case |
Control |
All |
||||
---|---|---|---|---|---|---|---|---|
N |
% |
N |
% |
N |
% |
N |
% |
|
Hispanic |
12682 |
12.73 |
126 |
7.51 |
56 |
8.74 |
12864 |
12.62 |
Asian/Pacific Islander |
13301 |
13.35 |
466 |
27.77 |
111 |
17.32 |
13878 |
13.61 |
African American |
27154 |
27.26 |
288 |
17.16 |
92 |
14.35 |
27534 |
27.01 |
Caucasian |
43907 |
44.07 |
762 |
45.41 |
367 |
57.25 |
45036 |
44.18 |
Other |
2579 |
2.59 |
36 |
2.15 |
15 |
2.34 |
2630 |
2.58 |
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process
25 July 2023
Serum | ||
Total number of subjects | Average volume (ml) per subject | |
Screening | 71,930 | 0.55 |
Comprehensive Clinical Exam | 2,237 | 2.91 |
Plasma | ||
Total number of subjects | Average volume (ml) per subject | |
Screening | 5 | 1.00 |
Comprehensive Clinical Exam | 2,225 | 1.21 |
Lymphocytes | ||
Total number of subjects | Average vials per subject | |
Screening | 5 | 3.60 |
Comprehensive Clinical Exam | 2,208 | 3.61 |
Buffy Coat | ||
Total number of subjects | Average vials per subject | |
Screening | 71,518 | 1.02 |
Comprehensive Clinical Exam | 2 | 1.00 |
Dried Buffy Coat | ||
Total number of subjects | Average vials per subject | |
Screening | 78,627 | 1.02 |
Comprehensive Clinical Exam | 2 | 1.00 |
DNA | |||
Total number of subjects | Average mass (µg) per subject | Average vials per subject | |
Screening | 1,975 | 110.31 | 1.43 |
Comprehensive Clinical Exam | 2,233 | 318.85 | 9.21 |
Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.
Resources Available
Specimens and Study DatasetsMaterials Available
- Buffy Coat
- DNA
- Dried Buffy Coat
- Lymphocytes
- Plasma
- Serum
- More Details
Study Documents
- Data Dictionary (PDF - 1.1 MB)
- Acceptability Protocol (PDF - 27.6 KB)
- Heirs Protocol (PDF - 258.4 KB)
- Laboratory Test Descriptions (PDF - 63.0 KB)
- Manual of Procedures (PDF - 3.3 MB)
- Forms
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.